Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immunogenicity of Non-mutated Ovarian Cancer-Specific Antigens

Version 1 : Received: 7 April 2024 / Approved: 8 April 2024 / Online: 8 April 2024 (15:41:08 CEST)

How to cite: Hesnard, L.; Thériault, C.; Cahuzac, M.; Durette, C.; Vincent, K.; Hardy, M.; Lanoix, J.; Lavallée, G.O.; Humeau, J.; Thibault, P.; Perreault, C. Immunogenicity of Non-mutated Ovarian Cancer-Specific Antigens. Preprints 2024, 2024040567. https://doi.org/10.20944/preprints202404.0567.v1 Hesnard, L.; Thériault, C.; Cahuzac, M.; Durette, C.; Vincent, K.; Hardy, M.; Lanoix, J.; Lavallée, G.O.; Humeau, J.; Thibault, P.; Perreault, C. Immunogenicity of Non-mutated Ovarian Cancer-Specific Antigens. Preprints 2024, 2024040567. https://doi.org/10.20944/preprints202404.0567.v1

Abstract

Epithelial ovarian cancer (EOC) has not significantly benefited from advances in immunotherapy, mainly because of the lack of well-defined actionable antigen targets. Using proteogenomic analyses of primary EOC tumors, we previously identified 91 aberrantly expressed tumor-specific antigens (TSAs) originating from unmutated genomic sequences. Most of these TSAs derive from non-exonic regions, and their expression results from cancer-specific epigenetic changes. The present study aimed to evaluate the immunogenicity of 48 TSAs selected according to two criteria: presentation by highly prevalent HLA allotypes and expression in a significant fraction of EOC tumors. Using targeted mass spectrometry analyses, we found that pulsing with synthetic TSA peptides leads to a high-level presentation on dendritic cells. TSA abundance correlated with the predicted binding affinity to the HLA allotype. We stimulated naïve CD8 T cells from healthy blood donors with TSA-pulsed dendritic cells and assessed their expansion with two assays: MHC-peptide tetramer staining and TCR Vβ CDR3 sequencing. We report that these TSAs can expand sizeable populations of CD8 T cells and, therefore, represent attractive targets for EOC immunotherapy.

Keywords

Tumor-specific antigen; Vaccine; Mass spectrometry; Antigen presentation; Immunogenicity; Dendritic cells

Subject

Medicine and Pharmacology, Immunology and Allergy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.